Go to the profile of Aruvant Sciences

Aruvant Sciences

NA, Aruvant

About Aruvant Sciences

Aruvant Sciences is a clinical-stage gene therapy company focused on hematological conditions, with an emphasis on helping patients suffering from sickle cell disease and β-thalassemia. ARU-1801, the lead candidate in Aruvant's pipeline, is an investigational lentiviral gene therapy for sickle cell disease and transfusion-dependent β-thalassemia. ARU-1801 incorporates a patented gene payload for a modified gamma-globin delivered into autologous stem cells via a proprietary vector construct, with the aim of restoring normal red blood cell function through increased levels of fetal hemoglobin. The high potency of the modified gamma globin enables ARU-1801 engraftment with only Reduced Intensity Conditioning (RIC).

Therapeutic Areas

Hepatic

Technologies

Other

Company Type

Biotechnology – R&D services

State of Ownership

Private

Sponsorship Group

Networker

Topics

Editions participated in:

June 2020